Tirzepatide the Treatment of Obesity

Diabetes is a metabolic disease characterized by hyperglycemia. Hyperglycemia is caused by a defect in insulin secretion or an impairment of its biological action, or both. Long-term hyperglycemia leads to chronic damage and dysfunction of various tissues, especially eyes, kidneys, heart, blood vessels and nerves. Eli Lilly recently announced that the U.S. Food and Drug Administration (FDA) has approved Mounjaro (tirzepatide) injection, a new, once-weekly GIP and GLP-1 receptor agonist, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes (T2D). Mounjaro has not been studied in patients with a history of pancreatitis and is not indicated for patients with type 1 diabetes (T1D). It is worth mentioning that Mounjaro is the first and only GIP/GLP-1 receptor agonist approved by FDA in the United States, which also represents the first new class of hypoglycemic drugs approved for marketing in the past decade. According to the third-quarter results released in October last year, Lilly submitted a priority review certificate (PRV) to the FDA to speed up the tirzepatide review, which can shorten the review cycle by four months. Currently, tirzepatide is also under regulatory review in the European Union, Japan, and several other markets.